netakimab vs secukinumab

NCT03598751 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 194 patients. The proportion of patients achieving a validated joint-response measure (ACR20) was overwhelmingly higher with netakimab than placebo, a gap large enough to leave no real doubt about the direction of the effect even though a formal statistical test was not reported in the source used.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT01392326 · Phase 3 · completed

In this large (n=606), randomized, quadruple-blind, placebo-controlled Phase 3 trial in active psoriatic arthritis, significantly more patients achieved an ACR20 response at week 24 on secukinumab 75 mg (50.5%) or 150 mg (50.0%) than on placebo (17.3%), a statistically significant difference for both doses (p<0.0001).

NCT03390101 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 213 participants and a clinical psoriasis endpoint (PASI 75) assessed at week 12. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.

NCT01358578 · Phase 3 · completed

This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry.